Teladoc Health (NYSE:TDOC) Stock Price Expected to Rise, Bank of America Analyst Says

Teladoc Health (NYSE:TDOC) had its price target boosted by stock analysts at Bank of America from $9.00 to $10.50 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the health services provider’s stock. Bank of America‘s price objective points to a potential upside of 13.02% from the company’s previous close.

Other equities research analysts also recently issued reports about the company. JPMorgan Chase & Co. cut their target price on Teladoc Health from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Friday, March 13th. Citigroup boosted their price objective on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 5th. Barclays cut their price objective on Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, March 26th. Weiss Ratings raised Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Teladoc Health from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Tuesday, March 10th. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $7.67.

Teladoc Health Stock Up 1.0%

Teladoc Health stock opened at $9.29 on Tuesday. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -9.58 and a beta of 2.10. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.75. The company’s 50-day moving average price is $7.26 and its two-hundred day moving average price is $6.30. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.77.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). The company had revenue of $613.85 million during the quarter, compared to analyst estimates of $611.04 million. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.The company’s revenue was down 2.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.53) earnings per share. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, analysts expect that Teladoc Health will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Fernando M. Rodrigues sold 5,677 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $43,315.51. Following the completion of the transaction, the insider owned 9,572 shares in the company, valued at $73,034.36. This trade represents a 37.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of Teladoc Health stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $60,322.78. Following the completion of the transaction, the insider directly owned 110,261 shares in the company, valued at $841,291.43. This represents a 6.69% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 39,195 shares of company stock valued at $299,058 over the last ninety days. 0.70% of the stock is currently owned by company insiders.

Institutional Trading of Teladoc Health

Several large investors have recently added to or reduced their stakes in TDOC. Monaco Asset Management SAM grew its holdings in Teladoc Health by 159.2% in the 4th quarter. Monaco Asset Management SAM now owns 1,956,947 shares of the health services provider’s stock valued at $13,699,000 after buying an additional 1,201,947 shares during the last quarter. Tejara Capital Ltd acquired a new stake in shares of Teladoc Health in the fourth quarter worth $1,114,000. Jupiter Asset Management Ltd. grew its stake in shares of Teladoc Health by 293.9% in the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock worth $27,021,000 after acquiring an additional 2,880,008 shares during the last quarter. Nano Cap New Millennium Growth Fund L P bought a new position in Teladoc Health during the fourth quarter worth $1,225,000. Finally, Union Square Park Capital Management LLC raised its stake in Teladoc Health by 233.3% during the 4th quarter. Union Square Park Capital Management LLC now owns 1,000,000 shares of the health services provider’s stock valued at $7,000,000 after purchasing an additional 700,000 shares during the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.